Posted by Michael Wonder on 11 Sep 2024
Evinacumab for the treatment of patients 12 years of age and older with homozygous familial hypercholesterolaemia
11 September 2024 - NICE has published final evidence-based recommendations on the use of evinacumab (Evkeeza) for the treatment of patients 12 years of age and older with homozygous familial hypercholesterolaemia.
Evinacumab, when used alongside diet and other low density lipoprotein cholesterol lowering therapies, is recommended as an option for the treatment of patients 12 years of age and older with homozygous familial hypercholesterolaemia. It is only recommended if Ultragenyx provides it according to the commercial arrangement.
